Omega-3 Index

If you eat fish a few times a week or take a fish oil supplement, you probably assume your omega-3 status is fine. The data says otherwise. Average levels in the US and Europe sit in the low range (around 4 to 5%), well below the range linked to lower heart disease and mortality risk in large cohort studies, and individual responses to the same dose of fish oil vary widely.

This test gives you a stable, long-term read on the EPA and DHA built into your red blood cell membranes, which tracks roughly 120 days of omega-3 status. It tells you whether your diet and supplements are actually moving the needle in your body, not just on your grocery receipt.

What the Omega-3 Index Actually Measures

The Omega-3 Index is the percentage of EPA (eicosapentaenoic acid) plus DHA (docosahexaenoic acid) in your red blood cell membranes, expressed as a share of total fatty acids. EPA and DHA are the two main marine-derived omega-3 fats, the kind concentrated in oily fish like salmon, sardines, and mackerel. It is not a hormone or a single molecule. It is a composite picture of how much long-chain omega-3 your body has actually incorporated into cell membranes.

Because red blood cells turn over slowly, the number reflects your habitual exposure over roughly four months rather than what you ate yesterday. That makes it conceptually similar to HbA1c (a long-term glucose marker), which is also measured in red blood cells and expressed as a percentage. It also has low biological variability and is not altered by whether you ate before the draw.

Heart Disease and Mortality

A higher Omega-3 Index has been consistently linked to lower cardiovascular risk and lower total mortality in large prospective cohort studies. The associations are large enough to matter, but they come from observational data. Randomized supplementation trials have produced more mixed results, with some, like STRENGTH, showing no benefit on major cardiovascular events. The discrepancy between observational biomarker studies and randomized trials remains an unresolved question in this field.

Sources: Framingham Heart Study (Harris 2018); 10-cohort analysis (Harris 2017); Fatty Acids and Outcomes Research Consortium (Harris 2021).

What this means for you: a low Omega-3 Index marks a risk profile that standard cholesterol numbers miss. In the Framingham analysis, the Omega-3 Index predicted mortality and new cardiovascular events even when total cholesterol in the same model did not.

Stroke Risk

A pooled analysis of 183,291 participants across 29 prospective studies found that people in the highest fifth of EPA levels had about 17% lower risk of total stroke and 18% lower risk of ischemic stroke compared with those in the lowest fifth. The association was specific to ischemic stroke, not hemorrhagic stroke. That said, randomized trials tell a different story: a Cochrane review of 31 supplementation trials concluded that omega-3 supplementation probably makes little or no difference to stroke risk, and may slightly increase hemorrhagic stroke risk. Higher blood levels track with lower observed stroke risk, but supplementing has not been shown to reduce it.

Kidney Function

Higher seafood-derived omega-3 levels are associated with lower risk of developing chronic kidney disease. In a pooled analysis of 19 cohorts, people in the top fifth of seafood omega-3 biomarker levels had about 13% lower risk of incident chronic kidney disease compared with those in the bottom fifth. Plant-derived omega-3 (ALA) did not show the same association, which underscores that this test, focused on EPA and DHA, is capturing something specific.

Peripheral Artery Disease

Evidence on omega-3 and peripheral artery disease is mixed. In a cross-sectional study of 179 patients, each absolute 1% drop in the Omega-3 Index was associated with 39% greater odds of having peripheral artery disease after adjusting for comorbidities and medications, and the index was inversely associated with CRP (high-sensitivity C-reactive protein, an inflammation marker) in that same population. However, a larger meta-analysis pooling the MESA and ARIC cohorts found no significant association between omega-3 polyunsaturated fatty acids and incident peripheral artery disease, and a Cochrane review found little or no effect of omega-3 supplementation on peripheral artery disease risk. The association in symptomatic patients is real but should not be read as causal or as established prospective risk.

Type 2 Diabetes and Insulin Sensitivity

In a meta-analysis of marine omega-3 biomarkers, higher EPA was associated with about 15% lower risk of type 2 diabetes and higher DPA (docosapentaenoic acid, another long-chain omega-3) was associated with about 16% lower risk. In a cross-sectional study of 47 middle-aged overweight men, those with a higher Omega-3 Index had 43% higher insulin sensitivity, 41% lower CRP, and 21% lower free fatty acids than those with a lower index.

Cognitive Aging and Dementia

In an older, dementia-free cohort, each one-standard-deviation higher plasma EPA+DHA was associated with about 13% lower risk of dementia and slower decline in global cognition, memory, and medial temporal lobe volume. Note that this finding was based on plasma EPA+DHA (a related but different measurement than the red blood cell Omega-3 Index). In a separate midlife population, a higher red blood cell Omega-3 Index was associated with larger hippocampal volumes and better abstract reasoning, although these brain findings were exploratory and differed by APOE (apolipoprotein E, a gene that influences how your body handles fats and Alzheimer's risk) genotype.

Why Standard Lipid Panels Miss This

A normal cholesterol or triglyceride panel does not tell you anything about your omega-3 status. In the Framingham analysis, the Omega-3 Index predicted mortality and cardiovascular events while total cholesterol in the same model did not. In a cohort of statin-treated patients with coronary disease, mean LDL-C was already under 80 mg/dL, but achieved plasma omega-3 index varied widely across patients, and only those reaching at least 4% saw protection against plaque progression in nondiabetic patients.

Diet questionnaires fall short for a different reason. A validated questionnaire was 100% sensitive for detecting low Omega-3 Index but only 66% specific, meaning it correctly identified people who actually had low levels but flagged many false alarms. Because absorption, metabolism, smoking, body weight, and genetics meaningfully shift how much EPA and DHA end up in your membranes, direct measurement is the only way to know where you actually stand.

Tracking Your Trend

One reading tells you where you are. The bigger value comes from tracking the Omega-3 Index over time, especially if you change your diet or start a supplement. Response is highly individual: heritability explains about 24% of the variability in the index, EPA+DHA intake about 25%, and fish oil supplementation about 15%. Two people taking the same supplement at the same dose can end up with very different blood levels.

Get a baseline. If you change your diet or start supplementing, retest at 3 to 6 months to see how much you actually moved, since red blood cell turnover takes roughly four months. After that, retest at least annually as part of a broader cardiometabolic check. Tracking the trend tells you whether your current strategy is working in your body, which is information that no fish oil bottle, food log, or generic dose recommendation can give you.

When Results Can Be Misleading

A single reading is more stable than most blood markers, but a few things can still complicate interpretation.

• Assay differences across labs: even small methodological differences between labs can produce meaningfully different numbers for the same blood sample. Reference categories from the original standardized method may not apply directly to a result from a different lab.
• Acute critical illness: in critically ill ICU patients, metabolic and inflammatory shifts can redistribute fats, and one study even found paradoxically higher omega-3 values in patients who later died. This is not a typical context for testing, but a recent hospitalization is a reason to wait before drawing conclusions.
• Statin therapy interactions: statins do not appear to lower the Omega-3 Index directly, but they can weaken the usual correlations between omega-3 levels and lipid markers, making interpretation alongside a lipid panel less straightforward.
• Specimen and method mismatch: the Omega-3 Index is specifically EPA+DHA in red blood cells. Plasma or whole-blood omega-3 tests, omega-6 to omega-3 ratios, and OmegaCheck-style panels are related but not interchangeable, and results across methods should not be compared directly.
• Observational vs. interventional evidence: higher blood levels track with lower observed risk for several outcomes, but randomized supplementation trials have produced more mixed results. The index is a useful status marker, but a single result is not a guarantee of cause-and-effect benefit from raising it.

Decision Pathway for Out-of-Pattern Results

If your Omega-3 Index comes back low, the next step is rarely to retest immediately. It is to look at the bigger picture. Pair the result with a standard lipid panel including ApoB (apolipoprotein B, a measure of all your atherogenic cholesterol-carrying particles), triglycerides, hs-CRP, fasting insulin, and HbA1c. A low Omega-3 Index combined with high ApoB, high triglycerides, or elevated hs-CRP describes a higher overall cardiovascular and metabolic risk pattern than any one marker alone.

If you already have known cardiovascular disease, peripheral artery disease, or chronic kidney disease, a low result is a stronger signal to have a focused conversation with a cardiologist or your primary clinician about whether targeted EPA+DHA intake fits your treatment plan. If you are planning a pregnancy or are pregnant, an OB-GYN can help interpret the result and tailor recommendations. The result that actually changes your health is the one you act on consistently over months, not the one you check most often.